25436-37-7

Basic information

• Product Name: 3-Pyridinecarboxylicacid,trimethylsilylester(9CI)
• Synonyms: 3-Pyridinecarboxylicacid,trimethylsilylester(9CI);Nicotinic acid trimethylsilyl ester;Pyridine-3-carboxylic acid trimethylsilyl ester
• CAS NO: 25436-37-7
• Molecular Formula: C9H13NO2Si
• Molecular Weight: 195.29
• Product Categories: SILYL
• Mol File: 25436-37-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Pyridinecarboxylicacid,trimethylsilylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarboxylicacid,trimethylsilylester(9CI)(25436-37-7)
• EPA Substance Registry System: 3-Pyridinecarboxylicacid,trimethylsilylester(9CI)(25436-37-7)

Safety Data

• Hazardous Substances Data: 25436-37-7(Hazardous Substances Data)

Upstream product

• 59-67-6 nicotinic acid 
• 999-97-3 1,1,1,3,3,3-hexamethyl-disilazane 
• 75-77-4 chloro-trimethyl-silane 
• 1450-14-2 1,1,1,2,2,2-hexamethyldisilane 

Downstream Products

• 17720-18-2 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridin-1-ium-3-carboxylate 

Relevant articles and documents

Stereoselective synthesis of nicotinamide β-riboside and nucleoside analogs

A stereoselective synthesis of β-anomers of nicotinamide riboside (NAR), its deamidated analog (NaR), and of a nicotinamide C-methylated riboside derivative (NA3′-C-MeR) was developed. The β-anomers of N-ribofuranosylnicotine-3-carboxamide (β-NAR) and its nicotinic acid analog (β-NaR) were obtained by stereoselective synthesis via glycosylation of the presilylated bases under Vorbruggen's protocol. A NAR analog, methylated in position 3 of the ribosylic moiety, is also reported.

NICOTINIC ACID RIBOSIDE OR NICOTINAMIDE RIBOSIDE COMPOSITIONS, REDUCED DERIVATIVES THEREOF, AND THE USE THEREOF TO ENHANCE SKIN PERMEATION IN TREATING SKIN CONDITIONS

Derivatives of nicotinic acid riboside (NAR), nicotinamide riboside (NR), and reduced NAR and NR, including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (4a), and compositions containing the same and/or reduced derivative forms of nicotinamide riboside including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-1,4-nicotinamide (2), are provided for use in the care of treatment of skin and skin conditions. In some embodiments, the invention relates to pharmaceutical compositions and cosmetic compositions containing one or more NR, NAR, NRH, or NARH derivatives, or prodrugs or salts thereof. In further embodiments, the invention relates to methods of using one or more NR, NAR, NRH, or NARH derivatives, or prodrugs, solvates, or salts thereof, to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival and overall cell and tissue health.

IPSO SUBSTITUTION OF HETEROCYCLIC TRIMETHYLSILYL CARBOXYLATES BY CARBON ELECTROPHILES

Trimethylsilyl esters 1 of heterocyclic carboxylic acids having the ester group in the α-position to an azine nitrogen atom react with aldehydes or ketones through ipso substitution of the ester group to give (trimethylsiloxy)-alkyl-substituted heterocyclic products in good yields.